Brief: Shenzhen Neptunus Interlong Bio-Technique Announces Passing Of Consistency Evaluation For Norfloxacin Capsules
11/01/2021 10:20
Jan 11 (Reuters) - Shenzhen Neptunus Interlong Bio-technique
Co Ltd 8329.HK :
* SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE ANNOUNCES
PASSING OF
CONSISTENCY EVALUATION FOR NORFLOXACIN CAPSULES BY NMPA
Source text for Eikon: urn:newsml:reuters.com:*:nHKS7GSTVQ
Further company coverage: 8329.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Neptunus Interlong Bio-technique
See all newsBrief: Shenzhen Neptunus Interlong Bio-Technique's Unit Enters Into JV Agreement With Huikang Bio-Technology
China's Neptunus Interlong H1 revenue falls
Brief: Shenzhen Neptunus Interlong Bio-Technique Expects Net Profit Attributable To Owners Of RMB 7 Million For 2026 Interim Period
Brief: Shenzhen Neptunus Interlong Bio-Technique Posts FY Loss & Total Comprehensive Expenses Attributable RMB40.7 Million
Brief: Shenzhen Neptunus Interlong Bio-Technique Sees FY Net Loss Attributable Of RMB40 Million